Shelagh B Coutts1, Véronique Dubuc2, Jennifer Mandzia2, Carol Kenney2, Andrew M Demchuk2, Eric E Smith2, Suresh Subramaniam2, Mayank Goyal2, Shivanand Patil2, Bijoy K Menon2, Philip A Barber2, Dar Dowlatshahi2, Thalia Field2, Negar Asdaghi2, Marie-Christine Camden2, Michael D Hill2. 1. From the Calgary Stroke Program, Departments of Clinical Neurosciences (S.B.C., V.D., J.M., C.K., A.M.D., E.E.S., S.S., M.G., B.K.M., P.A.B., M.D.H.), Radiology (S.B.C., A.M.D., E.E.S., M.G., S.P., B.K.M., M.D.H.), Community Health Sciences (E.E.S., M.D.H.), and Medicine (M.D.H.), and Hotchkiss Brain Institute (S.B.C., A.M.D., E.E.S., M.G., B.K.M., P.A.B., M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Medicine (Neurology), Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada (D.D.); Vancouver Stroke Program, Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada (T.F., N.A.); and Department of Neurosciences, Enfant-Jésus Hospital, Laval University, Quebec City, Quebec, Canada (M.-C.C.). scoutts@ucalgary.ca. 2. From the Calgary Stroke Program, Departments of Clinical Neurosciences (S.B.C., V.D., J.M., C.K., A.M.D., E.E.S., S.S., M.G., B.K.M., P.A.B., M.D.H.), Radiology (S.B.C., A.M.D., E.E.S., M.G., S.P., B.K.M., M.D.H.), Community Health Sciences (E.E.S., M.D.H.), and Medicine (M.D.H.), and Hotchkiss Brain Institute (S.B.C., A.M.D., E.E.S., M.G., B.K.M., P.A.B., M.D.H.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Medicine (Neurology), Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada (D.D.); Vancouver Stroke Program, Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada (T.F., N.A.); and Department of Neurosciences, Enfant-Jésus Hospital, Laval University, Quebec City, Quebec, Canada (M.-C.C.).
Abstract
BACKGROUND AND PURPOSE: Minor stroke and transient ischemic attack with an intracranial occlusion are associated with neurological deterioration and disability. Tenecteplase (TNK-tissue-type plasminogen activator) compared with alteplase is easier to administer, has a longer half-life, higher fibrin specificity, possibly a lower rate of intracranial hemorrhage, and may be an ideal thrombolytic agent in this population. METHODS: TNK-Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion (TEMPO-1) was a multicenter, prospective, uncontrolled, TNK-tissue-type plasminogen activator dose-escalation, safety, and feasibility trial. Patients with a National Institutes of Health Stroke Scale ≤5 within 12 hours of symptom onset, intracranial arterial occlusion on computed tomographic angiography and absence of well-evolved infarction were eligible. Fifty patients were enrolled; 25 patients at a dose of 0.1 mg/kg, and 25 patients at 0.25 mg/kg. Primary outcome was the rate of drug-related serious adverse events. Secondary outcomes included recanalization and 90-day neurological outcome (modified Rankin Scale, 0-1). RESULTS: Median baseline National Institutes of Health Stroke Scale was 2.5 (interquartile range, 1), and median age was 71 (interquartile range, 22) years. There were no drug-related serious adverse events in tier 1. In tier 2, there was 1 symptomatic intracranial hemorrhage (4%; 95% confidence interval, 0.01-20.0). Stroke progression occurred in 6% of cases. Overall, 66% had excellent functional outcome (modified Rankin Scale, 0-1) at 90 days. Recanalization rates were high; 0.1 mg/kg (39% complete and 17% partial), 0.25 mg/kg (52% complete and 9% partial). Complete recanalization was significantly related to excellent functional outcome (modified Rankin Scale, 0-1) at 90 days (relative risk, 1.65; 95% confidence interval, 1.09-2.5; P=0.026). CONCLUSIONS: Administration of TNK-tissue-type plasminogen activator in minor stroke with intracranial occlusion is both feasible and safe. A larger randomized controlled trial is needed to prove that this treatment is efficacious. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01654445.
BACKGROUND AND PURPOSE: Minor stroke and transient ischemic attack with an intracranial occlusion are associated with neurological deterioration and disability. Tenecteplase (TNK-tissue-type plasminogen activator) compared with alteplase is easier to administer, has a longer half-life, higher fibrin specificity, possibly a lower rate of intracranial hemorrhage, and may be an ideal thrombolytic agent in this population. METHODS: TNK-Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion (TEMPO-1) was a multicenter, prospective, uncontrolled, TNK-tissue-type plasminogen activator dose-escalation, safety, and feasibility trial. Patients with a National Institutes of Health Stroke Scale ≤5 within 12 hours of symptom onset, intracranial arterial occlusion on computed tomographic angiography and absence of well-evolved infarction were eligible. Fifty patients were enrolled; 25 patients at a dose of 0.1 mg/kg, and 25 patients at 0.25 mg/kg. Primary outcome was the rate of drug-related serious adverse events. Secondary outcomes included recanalization and 90-day neurological outcome (modified Rankin Scale, 0-1). RESULTS: Median baseline National Institutes of Health Stroke Scale was 2.5 (interquartile range, 1), and median age was 71 (interquartile range, 22) years. There were no drug-related serious adverse events in tier 1. In tier 2, there was 1 symptomatic intracranial hemorrhage (4%; 95% confidence interval, 0.01-20.0). Stroke progression occurred in 6% of cases. Overall, 66% had excellent functional outcome (modified Rankin Scale, 0-1) at 90 days. Recanalization rates were high; 0.1 mg/kg (39% complete and 17% partial), 0.25 mg/kg (52% complete and 9% partial). Complete recanalization was significantly related to excellent functional outcome (modified Rankin Scale, 0-1) at 90 days (relative risk, 1.65; 95% confidence interval, 1.09-2.5; P=0.026). CONCLUSIONS: Administration of TNK-tissue-type plasminogen activator in minor stroke with intracranial occlusion is both feasible and safe. A larger randomized controlled trial is needed to prove that this treatment is efficacious. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01654445.
Authors: Amy Y X Yu; Edwin Rogers; Meng Wang; Tolulope T Sajobi; Shelagh B Coutts; Bijoy K Menon; Michael D Hill; Eric E Smith Journal: Neurology Date: 2017-10-11 Impact factor: 9.910
Authors: Babikir Kheiri; Mohammed Osman; Ahmed Abdalla; Tarek Haykal; Sahar Ahmed; Mustafa Hassan; Ghassan Bachuwa; Mohammed Al Qasmi; Deepak L Bhatt Journal: J Thromb Thrombolysis Date: 2018-11 Impact factor: 2.300
Authors: D Byrne; G Sugrue; E Stanley; J P Walsh; S Murphy; E C Kavanagh; P J MacMahon Journal: AJNR Am J Neuroradiol Date: 2017-08-10 Impact factor: 3.825
Authors: Amy Y X Yu; Charlotte Zerna; Zarina Assis; Jessalyn K Holodinsky; Privia A Randhawa; Mohamed Najm; Mayank Goyal; Bijoy K Menon; Andrew M Demchuk; Shelagh B Coutts; Michael D Hill Journal: Neurology Date: 2016-07-06 Impact factor: 9.910
Authors: Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc Journal: Eur Stroke J Date: 2021-02-19
Authors: Ava L Liberman; Daniel Pinto; Sara K Rostanski; Daniel L Labovitz; Andrew M Naidech; Shyam Prabhakaran Journal: Neurohospitalist Date: 2018-09-13